InNexus Inc. and Genhelix to Combine Antibody Development and Manufacturing Resources

Published: Jul 10, 2009

LEON, Spain & BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (TSX Venture: IXS) (OTCBB: IXSBF) and Genhelix Biopharmaceutical Company announced today the signing of a Letter of Intent to set the stage for a planned strategic collaboration to focus on developing novel antibodies engineered with InNexus’ DXL™ technology.

Back to news